# Dualitas Therapeutics

> Dualitas Therapeutics is a South San Francisco biotechnology company building bispecific antibodies for immune and inflammatory disease. Its DualScreen engine tests large libraries of target pairs on cell surfaces, looking for proximity effects that a single antibody or a merely additive combination cannot create. Founded in 2023, the company emerged from stealth with a $65 million Series A, is advancing three preclinical programs led by DTX-102 in rheumatoid arthritis, and in September 2026 signed a Roche research and license collaboration carrying $36.5 million upfront and up to $1 billion in potential milestones, plus royalties.

- **Founded:** 2023
- **Headquarters:** South San Francisco, United States
- **Founders:** Greg Lazar, Ph.D. (Co-Founder and Chief Scientific Officer), Forbes Huang (Co-Founder, Chief Operating Officer and Chief Business Officer)
- **Products:** DualScreen Bispecific Discovery Engine, DTX-102, DTX-101, DTX-103, Proximity engager collaboration programs
- **Notable:** Founded in 2023 and emerged publicly in September 2025 with a $65 million Series A., Built a reusable library of proximity engager arms and three named preclinical programs from the DualScreen engine., Selected DTX-102 as lead development candidate and began IND-enabling studies, with clinical entry anticipated in 2027.

## Products & services

- **DualScreen Bispecific Discovery Engine** — A high-throughput discovery platform that functionally screens cell-surface target and epitope combinations, identifies synergistic proximity mechanisms, and supports rapid optimization into therapeutic bispecific formats. The company says internal screens can array more than 100,000 combinations; the Roche collaboration covers more than 300,000 combinations.
- **DTX-102** — The lead development candidate for rheumatoid arthritis, pairing an optimized anti-CD28 arm with an immune proximity engager. IND-enabling studies are underway and clinical entry is anticipated in 2027.
- **DTX-101** — A preclinical bispecific pairing an anti-IL-2Rbeta arm with a proximity engager, initially aimed at dermatologic and gastrointestinal autoimmune disease.
- **DTX-103** — A preclinical anti-FceRI bispecific with a proximity engager for allergic diseases including asthma, food allergy and chronic spontaneous urticaria; its mechanism is designed to work independently of IgE concentration.
- **Proximity engager collaboration programs** — Partnered discovery ranging from existing pipeline programs to de novo bispecific discovery and disease areas beyond the company's internal I&I focus. Roche is the first publicly announced research and license partner.

## Achievements

- Founded in 2023 and emerged publicly in September 2025 with a $65 million Series A.
- Built a reusable library of proximity engager arms and three named preclinical programs from the DualScreen engine.
- Selected DTX-102 as lead development candidate and began IND-enabling studies, with clinical entry anticipated in 2027.
- Signed Roche as its first publicly announced partner in a 2026 collaboration covering more than 300,000 bispecific combinations.
- Secured $36.5 million upfront in the Roche deal, with up to $1 billion in potential total deal value plus tiered royalties.
- Installed immunology veteran Karim Dabbagh as CEO in June 2026 while former interim CEO Rich Murray remained on the board.

## Latest updates

- **2026-09** — Announced a Roche research and license collaboration to screen more than 300,000 I&I bispecific combinations, with $36.5 million upfront and potential total deal value up to $1 billion plus tiered royalties.
- **2026-06** — Appointed Karim Dabbagh as CEO, named DTX-102 the lead development candidate for rheumatoid arthritis, disclosed DTX-101, and said DTX-102 clinical studies were anticipated in 2027.
- **2025-09** — Launched from stealth with a $65 million Series A co-led by Versant Ventures and Qiming Venture Partners USA.

## Links

- Website: https://www.dualitastx.com/
- LinkedIn: https://www.linkedin.com/company/dualitas-therapeutics

---

Profile page: https://yespress.io/dualitas-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-09-24